Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients

Journal of Clinical Pharmacology

Volumn 47, Issue 1, 2007, Pages 101-111

  Booth, Brian P ^a   Rahman, Atiqur ^a   Dagher, Ramzi ^a   Griebel, Donna ^b   Lennon, Shari ^c   Fuller, David ^d   Sahajwalla, Chandra ^a   Mehta, Mehul ^a   Gobburu, Jogarao V S ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Oncology and Transplant   (United States)

^d Genzyme Europe Research   (United Kingdom)

Author keywords

Busulfan; Dosing; Modeling; Pediatrics; Pharmacokinetics

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE;

ADOLESCENT; ARTICLE; BODY SURFACE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG TARGETING; FEMALE; GENDER AND SEX; HUMAN; MALE; MONTE CARLO METHOD; MULTIPLE CYCLE TREATMENT; PATIENT COMPLIANCE; POPULATION MODEL;

AGE FACTORS; ALKYLATING AGENTS; BODY SURFACE AREA; BODY WEIGHT; BUSULFAN; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; MONTE CARLO METHOD; NEOPLASMS; SEX FACTORS;

EID: 33845753369     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006295789     Document Type: Article

References (37)

1. Hassan M. The role of busulfan in bone marrow transplantation. Med Oncol. 1999 ; 16: 166-176.
2. Schuler US, Renner UD, Kroschinsky F, et al. Intravenous busulfan for conditioning before autologous or allogeneic human blood stem cell transplantation. Br J Haematol. 2001 ; 114: 944-950.
3. Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione-S-transferase α, μ, and φ. Drug Metab Dispos. 1996 ; 24: 1015-1019.
4. Gibbs JP, Murray G, Risler L, Chien JY, Dev R, Slattery JT. Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan. Cancer Res. 1997 ; 57: 5509-5516.
5. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: influence of plasma busulfan levels on the outcome of transplantation. Blood. 1997 ; 89: 3055-3060.
6. Grochow LB, Jones RJ, Brundrett RB, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol. 1989 ; 25: 55-61.
7. DeMagalhaes-Silverman M, Bloom EJ, Donnenberg A, et al. Toxicity of busulfan and cyclophosphamide in patients with hematologic malignancies. Bone Marrow Transplant. 1996 ; 17: 329-333.
8. Tran HT, Madden T, Petropoulos D, et al. Individualizing high-dose oral busulfan: prospective dose adjustment in a pediatric population undergoing allogeneic stem cell transplantation fro advanced hematological malignancies. Bone Marrow Transplant. 2000 ; 26: 463-470.
9. Bleyzac N, Souillet G, Magron P, et al. Improved clinical outcome of pediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant. 2001 ; 28: 743-751.
10. Hassan M, Fasth A, Gerritsen B, et al. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. Bone Marrow Transplant. 1996 ; 18: 843-850.
11. Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C. IV busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant. 2004 ; 33: 979-987.
12. Slattery JT, Risler LJ. Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. Ther Drug Monit. 1998 ; 20: 543-549.
13. Davidian M, Giltman D. Models for Repeated Measurement Data. London, UK: Chapman and Hall ; 1995.
14. Beal SL, Sheiner LB. NONMEM User's Guides (I-III). Hanover, Md: ICON ; 1998.
15. Barker CC, Butzner JD, Anderson RA, Brant R, Sauve RS. Post-transplant complications: incidence, survival and risk factors for the development of veno-occlusive disease in pediatric hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2003 ; 32: 79-87.
16. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science. 1997 ; 276: 122-126.
17. Hassan M, Oberg G, Bjorkholm M, Wallin I, Lindgren M. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol. 1993 ; 33: 181-186.
18. Hoffer E, Akria L, Tabak A, Scherb I, Rowe JM, Krivoy N. A simple approximation for busulfan dose adjustment in adult patients undergoing bone marrow transplantation. Ther Drug Monit. 2004 ; 26: 331-335.
19. McCune JS, Gooley T, Gibbs JP, et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2002 ; 30 ; 167-173.
20. Gibbs JP, Czerwinski M, Slattery JT. Busulfan-glutathione conjugation catalyzed by human liver cytosolic glutathione-S-transferases. Cancer Res. 1996 ; 56: 3678-3681.
21. Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione-S-transferase α, μ, and φ. Drug Metab Dispos. 1996 ; 24: 1015-1019.
22. Kusama M, Kubota T, Matsukura Y, et al. Influence of glutathione-S- transferase A1 polymorphism on the pharmacokinetics of busulfan. Clin Chimica Acta. 2006 ; 368: 93-98.
23. Chen CL, Lui Q, Pui CH, et al. Higher frequency of glutathione-S- transferase deletions in black children with acute lymphoblastic leukemia. Blood. 1997 ; 89: 1701-1707.
24. Vassal G, Fischer A, Challine D, et al. Busulfan disposition below the age of three: alteration in children with lysosomal storage disease. Blood. 1993 ; 82: 1030-1034.
25. Hassan M, Oberg G, Bekassy AN, et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol. 1991 ; 28: 130-134.
26. Grochow LB, Krivit W, Whitley CB, Blazar B. Busulfan disposition in children. Blood. 1990 ; 75: 1723-1727.
27. Sandstrom M, Karlsson MO, Ljungman P, et al. Population pharmacokinetic analysis resulting in a tool for dose individualization of busulphan in bone marrow transplantation recipients. Bone Marrow Transplant. 2001 ; 28: 657-664.
28. Schiltmeyer B, Klingebiel T, Schwab M, et al. Population pharmacokinetics of oral busulfan in children. Cancer Chemother Pharmacol. 2003 ; 52: 209-216.
29. Cremers S, Schoemaker R, Bredius R, et al. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. Br J Clin Pharmacol. 2002 ; 53: 386-389.
30. Oechtering D, Schiltmeyer B, Hempel G, et al. Toxicity and pharmacokinetics of i.v. busulfan in children before stem cell transplantation. Anticancer Drugs. 2005 ; 16: 337-344.
31. McCune JS, Gibbs JP, Slattery JT. Plasma concentration monitoring of busulfan: does it improve clinical outcome? Clin Pharmacokinet. 2000 ; 39: 155-165.
32. Grochow LB. Parenteral busulfan: is therapeutic monitoring still warranted? Biol Blood Bone Marrow Transplant. 2002 ; 8: 465-467.
33. Busulfex [package insert]. Fremont, Calif: PDL BioPharma; 2002.
34. Bolinger AM, Zangwill AB, Slattery JT, et al. Target dose adjustment of busulfan in pediatric patients undergoing bone marrow transplantation. Bone Marrow Transplant. 2001 ; 28: 1013-1018.
35. Vaughan WP, Carey D, Perry S, Westfall AO, Salzman DE. A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan. Biol Blood Marrow Transplant. 2002 ; 8: 619-624.
36. Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance for Industry: Population Pharmacokinetics. Rockville, Md: Center for Drug Evaluation and Research, US Food and Drug Administration ; 1999.
37. Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance for Industry: Exposure-Response Relationships - Study Design, Data Analysis, and Regulatory Applications. Rockville, Md: Center for Drug Evaluation and Research, US Food and Drug Administration ; 2003.